This Chinese Startup Completes Series B Financing For Oncolytic Virus Development
Immvira Group Company announced this week the completion of series B financing for $58 million. The biotechnology startup focuses on the development of new generation oncolytic viruses as potential cancer therapeutics. Immvirva attracted a number of biotech investors. This round of financing was led by Huagai Capital, with participation by Apricot Capital, Cowin Capital. The funds … Read more